

Table 1. Baseline characteristics of participants with NAFLD.

	Overall population N=259	Training Set N=173	Validation Set N=86	P value
Demographics				
Age, years	42.8 ± 13.7	42.5 ± 13.0	43.6 ± 15.2	0.540
Men, n (%)	188 (72.6%)	131 (75.7%)	57 (66.3%)	0.109
Metabolic factors				
BMI, kg/m ²	26.7 ± 3.2	26.6 ± 3.1	26.8 ± 3.5	0.712
Waist circumference, cm	92.2 ± 8.9	92.4 ± 8.9	91.6 ± 9.0	0.489
Central obesity, n (%)	222 (85.7%)	146 (84.3%)	76 (88.4%)	0.389
Type 2 diabetes, n (%)	98 (37.8%)	65 (37.6%)	33 (38.4%)	0.901
Hypertension, n (%)	77 (29.7%)	47 (27.2%)	30 (34.9%)	0.201
Metabolic syndrome, n (%)	193 (74.5%)	120 (69.4%)	73 (88.4%)	0.007
Laboratory parameters				
ALT, IU/L	49 (28-90)	48 (27-87)	55 (30-93)	0.285
AST, IU/L	34 (24-56)	33 (24-52)	37 (27-60)	0.068
γ-GT, IU/L	53 (30-87)	45 (29-77)	64 (39-109)	0.003
Albumin, g/L	4.5 ± 0.5	4.5 ± 0.4	4.5 ± 0.5	0.351
Bilirubin, μmol/L	14.2 ± 9.8	13.7 ± 6.4	15.3 ± 14.4	0.215
Fasting glucose, mmol/L	5.8 ± 1.7	5.8 ± 1.7	5.9 ± 1.6	0.753
Fasting insulin, mIU/L	14.4 (9.0- 20.7)	14.4 (9.1-20.8)	14.4 (9.0-20.5)	0.855
HbA1c, %	6.5 ± 1.8	6.5 ± 1.7	6.5 ± 1.9	0.997
HOMA-IR	3.5 (2.3- 5.3)	3.5 (2.3-5.2)	3.6 (2.1-5.4)	0.803
Prothrombin time, sec	12.9 ± 0.7	12.9 ± 0.6	12.9 ± 0.7	0.384
Platelet count, ×10 ⁹ /L	243 ± 69	237.5 ± 66.3	253.3 ± 72.1	0.081
TG, mmol/L	2.2 ± 2.1	2.1 ± 2.3	2.3 ± 1.8	0.464

TC, mmol/L	5.1 ± 1.1	5.1 ± 1.1	5.1 ± 1.2	0.980
HDL-C, mmol/L	1.0 ± 0.2	1.0 ± 0.2	1.0 ± 0.2	0.414
LDL-C, mmol/L	3.0 ± 0.9	3.0 ± 0.8	2.9 ± 1.0	0.328
CK18-M30, IU/L	156 (79-329)	141 (80-297)	159 (79-371)	0.477
<i>iLivTouch</i> parameters				
UAP, dB/m ²	310 ± 22	311 ± 21	309 ± 25	0.489
LSM, kPa	10.5 ± 4.8	9.7 ± 3.7	12.0 ± 6.2	<0.001
Liver histology				
Length of liver biopsy specimen (cm)	1.5 (1.5- 2.0)	1.5 (1.5- 2.0)	1.5 (1.5- 2.0)	0.601
Fibrosis stage, n (%)				0.836
F0	53 (20.5%)	35 (20.2%)	18 (20.9%)	
F1	138 (53.3%)	93 (53.8%)	45 (52.3%)	
F2	49 (18.9%)	32 (18.5%)	17 (19.8%)	
F3	13 (5.0%)	10 (5.8%)	3 (3.5%)	
F4	6 (2.3%)	3 (1.7%)	3 (3.5%)	
Steatosis grade, n (%)				0.887
S0	44 (17.0%)	31 (17.9%)	13 (15.1%)	
S1	92 (35.5%)	60 (34.7%)	32 (37.2%)	
S2	50 (19.3%)	32 (18.5%)	18 (20.9%)	
S3	73 (28.2%)	50 (28.19%)	23 (26.7%)	
Ballooning grade, n (%)				0.363
B0	49 (18.9%)	29 (16.8%)	20 (23.3%)	
B1	128 (49.4%)	90 (52.0%)	38 (44.2%)	
B2	82 (31.7%)	54 (31.2%)	28 (32.6%)	
Lobular inflammation grade,				0.470

n (%)				
L0	28 (10.8%)	20 (11.6%)	8 (9.3%)	
L1	174 (67.2%)	119 (68.8%)	55 (64.0%)	
L2	56 (21.6%)	33 (19.1%)	23 (26.7%)	
L3	1 (0.4%)	1 (0.6%)	0 (0.0%)	
NAS score	4 (3- 5)	4 (3-5)	4 (3-5)	0.740
NASH[†]	100 (38.6%)	63 (36.4%)	37 (43.0%)	0.304
NASH with fibrosis[‡]	90 (34.7%)	57 (32.9%)	33 (38.4%)	0.388

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CK-18, cytokeratin-18 fragments; GGT, γ -glutamyltranspeptidase; HOMA-IR, homeostasis model assessment-insulin resistance; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NASH, nonalcoholic steatohepatitis; NAS, NAFLD activity score; TG, triglycerides; TC, total cholesterol; UAP, ultrasound attenuation parameter; LSM, liver stiffness measurement.

[†]NASH was defined as the presence of hepatic steatosis, lobular inflammation and ballooning with NAS \geq 5.

[‡]NASH with fibrosis was defined as presence of NASH and any histological stage of fibrosis (F \geq 1 fibrosis).